Baker Bros. Advisors’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-22,430
| Closed | -$3.86M | – | 126 |
|
|
2021
Q3 | $3.86M | Hold |
22,430
| – | – | 0.02% | 104 |
|
|
2021
Q2 | $2.81M | Hold |
22,430
| – | – | 0.01% | 107 |
|
|
2021
Q1 | $3.04M | Hold |
22,430
| – | – | 0.01% | 108 |
|
|
2020
Q4 | $2.87M | Sell |
22,430
-3,210
| -13% | -$376K | 0.01% | 106 |
|
|
2020
Q3 | $2.88M | Sell |
25,640
-1,360
| -5% | -$135K | 0.01% | 93 |
|
|
2020
Q2 | $2.57M | Hold |
27,000
| – | – | 0.01% | 95 |
|
|
2020
Q1 | $2.43M | Buy |
+27,000
| New | +$2.1M | 0.01% | 85 |
|
|
2019
Q4 | – | Sell |
-83,900
| Closed | -$3.31M | – | 109 |
|
|
2019
Q3 | $3.31M | Hold |
83,900
| – | – | 0.02% | 74 |
|
|
2019
Q2 | $3.45M | Hold |
83,900
| – | – | 0.02% | 70 |
|
|
2019
Q1 | $3.91M | Hold |
83,900
| – | – | 0.03% | 65 |
|
|
2018
Q4 | $3.65M | Hold |
83,900
| – | – | 0.03% | 61 |
|
|
2018
Q3 | $4.8M | Sell |
83,900
-80,000
| -49% | -$3.93M | 0.03% | 72 |
|
|
2018
Q2 | $7.95M | Hold |
163,900
| – | – | 0.06% | 59 |
|
|
2018
Q1 | $6.41M | Hold |
163,900
| – | – | 0.05% | 69 |
|
|
2017
Q4 | $6.96M | Hold |
163,900
| – | – | 0.06% | 68 |
|
|
2017
Q3 | $6.12M | Buy |
163,900
+135,135
| +470% | +$4.69M | 0.05% | 72 |
|
|
2017
Q2 | $874K | Hold |
28,765
| – | – | 0.01% | 103 |
|
|
2017
Q1 | $761K | Hold |
28,765
| – | – | 0.01% | 104 |
|
|
2016
Q4 | $734K | Hold |
28,765
| – | – | 0.01% | 117 |
|
|
2016
Q3 | $1.04M | Hold |
28,765
| – | – | 0.01% | 111 |
|
|
2016
Q2 | $977K | Hold |
28,765
| – | – | 0.01% | 117 |
|
|
2016
Q1 | $759K | Hold |
28,765
| – | – | 0.01% | 120 |
|
|
2015
Q4 | $1.4M | Hold |
28,765
| – | – | 0.01% | 114 |
|
|
2015
Q3 | $716K | Hold |
28,765
| – | – | 0.01% | 124 |
|
|
2015
Q2 | $910K | Hold |
28,765
| – | – | 0.01% | 118 |
|
|
2015
Q1 | $1.09M | Hold |
28,765
| – | – | 0.01% | 119 |
|
|
2014
Q4 | $1.12M | Hold |
28,765
| – | – | 0.01% | 112 |
|
|
2014
Q3 | $870K | Hold |
28,765
| – | – | 0.01% | 101 |
|
|
2014
Q2 | $977K | Hold |
28,765
| – | – | 0.01% | 99 |
|
|
2014
Q1 | $992K | Sell |
28,765
-1,235
| -4% | -$55.7K | 0.01% | 99 |
|
|
2013
Q4 | $1.19M | Buy |
+30,000
| New | +$724K | 0.02% | 87 |
|
Baker Bros. Advisors's XLRN Position: Q4 2021 in Review
Baker Bros. Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 22,430 shares — an estimated $3.86M sold.
Baker Bros. Advisors first reported a position in XLRN in Q4 2013 and held it in 31 quarters. The position peaked at $7.95M in Q2 2018. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Baker Bros. Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Baker Bros. Advisors sold 22,430 Acceleron Pharma shares in Q4 2021, an estimated $3.86M.
- Baker Bros. Advisors first reported a position in Acceleron Pharma in Q4 2013 and held it in 31 quarters.
- Baker Bros. Advisors's Acceleron Pharma position peaked at $7.95M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.